Archives
-
Fluconazole: A Systems View of Biofilm Resistance
2026-09-02
Fluconazole can do more than benchmark fungal growth inhibition: it can help connect ergosterol stress with biofilm physiology and antifungal drug resistance. This article translates PP2A–autophagy findings into a mechanistically resolved assay strategy for Candida research.
-
Aprotinin in GRO-seq Workflow Design
2026-09-01
Aprotinin adds a defined, reversible serine-protease control to nuclei-based workflows without pretending to replace RNase protection or the validated GRO-seq chemistry. This guide translates the rRNA-depleted wheat GRO-seq method into practical pilot designs for protease-sensitive sample preparation, fibrinolysis studies, and inflammatory assay troubleshooting.
-
YC-1: HIF-1α and sGC Research Guide
2026-09-01
YC-1, also known as 5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol, is a dual-action research compound that activates soluble guanylyl cyclase and suppresses HIF-1α signaling. Peer-reviewed studies support its use for hypoxia, tumor angiogenesis inhibition, apoptosis and cancer biology research, while recent mouse data extend HIF-1α pathway investigation into postoperative cognitive dysfunction.
-
5-(N,N-dimethyl)-Amiloride in Endothelial Injury
2026-08-31
A translational framework for using 5-(N,N-dimethyl)-Amiloride hydrochloride to interrogate Na+/H+ exchanger biology across sepsis-related endothelial injury and cardiac ischemia-reperfusion models.
-
Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
2026-08-31
This dual-component reagent helps preserve protein phosphorylation states during lysate preparation for immunoblotting, immunoprecipitation, kinase activity assays, and mass spectrometry. It is intended for scientific research workflows only; it should not be used for diagnostic, therapeutic, or medical applications.
-
SOAT1, Lipophagy, and PHMG Pulmonary Fibrosis
2026-08-30
A 2026 Biochemical Pharmacology study identifies SOAT1 as a mechanistic link between PHMG exposure, alveolar-macrophage cholesterol ester accumulation, impaired lipophagy, and pulmonary fibrosis. Its mouse, macrophage, and pharmacological-inhibition experiments support SOAT1 as a preclinical intervention target, while also defining important limits for translation to human disease.
-
Ozone, Efferocytosis, and Neuropathic Pain Mechanisms
2026-08-29
A 2024 Frontiers in Immunology study links ozone treatment to improved macrophage efferocytosis and reduced neuropathic pain in a chronic constriction injury model. Its mechanistic contribution is the proposed AMPK/Gas6-MerTK/SOCS3 axis, which connects apoptotic-cell clearance with suppression of inflammatory cytokines.
-
Merimepodib (VX-497): Reading IMPDH Biology
2026-08-28
Merimepodib (VX-497) is more than an IMPDH inhibitor: it is a mechanistic probe for guanine nucleotide dependence across viral replication, lymphocyte biology, and cancer research. This article explains how metabolic context, genetic validation, and guanosine rescue improve interpretation of IMPDH assays.
-
Minoxidil sulphate for Vascular Assays
2026-08-28
Minoxidil sulphate is an active-metabolite tool for connecting potassium-channel pharmacology with vascular reactivity and hair follicle models. This guide translates renal sepsis findings into practical workflows, stock-preparation safeguards, comparative controls, and troubleshooting strategies for reproducible research.
-
Annexin V-PE Reagent for Reliable Cell Death Assays
2026-08-27
Learn how Annexin V-PE Reagent, SKU K2280, supports practical phosphatidylserine externalization detection in flow cytometry and fluorescence microscopy. This scenario-based guide covers assay design, controls, interpretation, storage, and vendor-selection considerations for reproducible apoptosis and cell death studies.
-
CAPE Inhibits TcdB and Modulates CDI
2026-08-27
The reference study identifies caffeic acid phenethyl ester (CAPE) as a candidate inhibitor of Clostridioides difficile toxin B (TcdB), combining cell-based screening with biochemical, animal, microbiota, and metabolite analyses. Its main implication is that toxin neutralization and restoration of infection-associated microbial disruption may complement conventional antibacterial approaches, although the binding evidence and in vivo effects require further validation.
-
11β-HSD1 Inhibition in Liver Fibrosis
2026-08-26
A 2025 Archives of Pharmacal Research study identifies a dual mechanism by which a novel 11β-HSD1 inhibitor attenuates liver fibrosis in mice: reduced intracellular cortisol suppresses Notch signaling and enhances natural killer cell-mediated clearance of activated hepatic stellate cells. The findings connect local glucocorticoid metabolism with immune remodeling and provide a mechanistic framework for evaluating new antifibrotic strategies.
-
Carvedilol in Reliable Cell and HCT Assays
2026-08-26
Learn how Carvedilol (SKU B1332) can improve experimental interpretation across receptor, oxidative-stress, vascular, and hematopoietic assays. This scenario-based guide covers concentration selection, solvent handling, assay controls, translational limitations, and practical reagent selection.
-
Neurotensin: An Assay Design Framework
2026-08-25
Neurotensin is a Neurotensin receptor 1 activator suited to mechanistic studies of GPCR trafficking and miRNA responses. This guide connects endpoint selection, peptide handling, and spectral quality control.
-
Removing Pollen Interference in EEM Bioaerosol Detection
2026-08-25
Zhang et al. developed a fluorescence-data workflow that combines spectral preprocessing, feature transformation, and random forest classification to reduce pollen interference in hazardous bioaerosol identification. Fast Fourier transform processing improved the reported classification performance to 89.24%, helping distinguish pathogens and toxins in complex excitation–emission matrix datasets.